Market, risk, enforcement
AI is already being used in pharma quality work. The risk is not that AI exists. The risk is when people treat it as a substitute for GMP judgement. Regulators have now drawn that line, and they have enforced it.
The gap in most tools
The usual promises are faster drafting, faster search, better knowledge lookup, SOP summaries, and automated regulatory writing. All useful. But a GMP decision needs more than that. It needs the strongest sources used first, a clear position, hard rules, traceability, a named human who is accountable, and control over the data.
The real GMP risk is not that AI exists. It is leaning on AI output without checking it, inside a quality system.
The enforcement lesson
In an April 2026 warning letter to a drug manufacturer, the FDA recorded that the firm had used AI agents to create drug product specifications, procedures, and master production and control records meant to meet FDA requirements. It is among the first publicly reported times the FDA has cited the use of AI itself in manufacturing.
The FDA was clear. If AI is used to help draft documents, the firm still has to review those documents to make sure they are accurate and actually meet CGMP. The failure to do that was cited under 21 CFR 211.22(c), the rule that sets out what the quality control unit is responsible for. Overreliance on AI was also recorded. In one widely reported example, the firm said it had not done process validation because the AI agent had not told them it was required.
The citation was not a new AI rule. It applied a principle that has been there for decades: a qualified human, accountable to a defined quality system, owns the output.
Source: FDA Warning Letter (Purolea Cosmetics Lab, 04/02/2026), and industry analysis from RAPS, ECA Academy, and others. Read the letter →
The lesson is not "do not use AI." It is that the quality unit still owns the output. The FDA's concern was leaning on AI without checking it, no real quality oversight, and AI-generated GMP documents that were never verified. Those are exactly the failure modes a serious GMP AI tool has to design against.
How ChatQP answers this
| Risk shown by the enforcement | What ChatQP does |
|---|---|
| AI used in place of GMP knowledge | It is decision support only. It is not a certification authority. |
| AI output not properly reviewed | QP review is required. Outputs are there to be reviewed, not to decide. |
| AI-generated documents not verified | Outputs cite their sources and spell out the evidence needed and the actions required. |
| AI did not know a legal requirement | The hard GMP rules are written in code, outside the model. |
| No real quality oversight | Built around a QP and QA review workflow. |
It is controlled, local, auditable decision support, with a qualified human in charge.
See how ChatQP works Annex 22 and AI governance